Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Target Price at $20.88

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been given an average rating of “Hold” by the five research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $20.8750.

Several brokerages have issued reports on HCM. Zacks Research lowered HUTCHMED from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 9th. Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Morgan Stanley lowered HUTCHMED from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $18.00 to $13.75 in a research note on Monday, September 22nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a research note on Wednesday, October 8th.

Institutional Trading of HUTCHMED

Several institutional investors have recently added to or reduced their stakes in HCM. Jane Street Group LLC increased its holdings in shares of HUTCHMED by 128.0% in the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after buying an additional 124,771 shares during the period. UBS Group AG grew its position in HUTCHMED by 112.8% during the 3rd quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after acquiring an additional 72,614 shares during the last quarter. Amundi increased its stake in HUTCHMED by 41.9% in the 3rd quarter. Amundi now owns 223,330 shares of the company’s stock worth $3,620,000 after purchasing an additional 65,898 shares during the period. ABN Amro Investment Solutions bought a new stake in HUTCHMED in the second quarter valued at approximately $962,000. Finally, Tema Etfs LLC bought a new stake in HUTCHMED in the second quarter valued at approximately $641,000. 8.82% of the stock is currently owned by hedge funds and other institutional investors.

HUTCHMED Stock Up 1.5%

NASDAQ HCM opened at $13.55 on Wednesday. The company has a quick ratio of 4.51, a current ratio of 4.65 and a debt-to-equity ratio of 0.05. HUTCHMED has a 52-week low of $11.51 and a 52-week high of $19.50. The company has a fifty day moving average of $14.55 and a 200-day moving average of $15.66.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.